Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis.
Kaiwu XuCailing XiangZhige YuJia LiChangjun LiuPublished in: ImmunoTargets and therapy (2024)
Synchronous administration of lenvatinib and PD-1 inhibitors improved survival rate significantly. The synchronous combination could represent a promising strategy in HCC beyond oligometastasis.
Keyphrases